Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2012

Open Access 01-12-2012 | Primary research

Acute myeloid leukemia and transcription factors: role of erythroid Krüppel-like factor (EKLF)

Authors: Rosa Ayala, Joaquin Martínez-López, Florinda Gilsanz

Published in: Cancer Cell International | Issue 1/2012

Login to get access

Abstract

We have investigated the role of erythroid transcription factors mRNA expression in patients with acute myeloid leukemia (AML) in the context of cytogenetic and other prognostic molecular markers, such as FMS-like Tyrosine Kinase 3 (FLT3), Nucleophosmin 1 (NPM1), and CCAAT/enhance-binding protein α (CEBPA) mutations. Further validation of Erythroid Krüppel-like Factor (EKLF) mRNA expression as a prognostic factor was assessed.
We evaluated GATA binding protein 1 (GATA1), GATA binding protein 2 (GATA2), EKLF and Myeloproliferative Leukemia virus oncogen homology (cMPL) gene mRNA expression in the bone marrow of 65 AML patients at diagnosis, and assessed any correlation with NPM1, FLT3 and CEBPA mutations. EKLF-positive AML was associated with lower WBC in peripheral blood (P = 0.049), a higher percentage of erythroblasts in bone marrow (p = 0.057), and secondary AMLs (P = 0.036). High expression levels of EKLF showed a trend to association with T-cell antigen expression, such as CD7 (P = 0.057). Patients expressing EKLF had longer Overall Survival (OS) and Event Free Survival (EFS) than those patients not expressing EKLF (median OS was 35.61 months and 19.31 months, respectively, P = 0.0241; median EFS was 19.80 months and 8.03 months, respectively, P = 0.0140). No correlation of GATA1, GATA2, EKLF and cMPL levels was observed with FLT-3 or NPM1 mutation status. Four of four CEBPA mutated AMLs were EKLF positive versus 10 of 29 CEBPA wild-type AMLs; three of the CEBPA mutated, EKLF-positive AMLs were also GATA2 positive. There were no cases of CEBPA mutations in the EKLF-negative AML group. In conclusion, we have validated EKLF mRNA expression as an independent predictor of outcome in AML, and its expression is not associated with FLT3-ITD and NPM1 mutations. EKLF mRNA expression in AML patients may correlate with dysregulated CEBPA.
Appendix
Available only for authorised users
Literature
1.
Miller IJ, Bieker JJ: A novel, erythroid cell-specific murine transcription factor that binds to the CACCC element and is related to the Kruppel family of nuclear proteins. Mol Cell Biol. 1993, 13 (5): 2776-2786.PubMedCentralCrossRefPubMed
2.
Bouilloux F, Juban G, Cohet N, Buet D, Guyot B, Vainchenker W, Louache F, Morle F: EKLF restricts megakaryocytic differentiation at the benefit of erythrocytic differentiation. Blood. 2008, 112 (3): 576-584. 10.1182/blood-2007-07-098996.CrossRefPubMed
3.
Isern J, Fraser ST, He Z, Zhang H, Baron MH: Dose-dependent regulation of primitive erythroid maturation and identity by the transcription factor Eklf. Blood. 2010, 116 (19): 3972-3980. 10.1182/blood-2010-04-281196.PubMedCentralCrossRefPubMed
4.
Drissen R, Guyot B, Zhang L, Atzberger A, Sloane-Stanley J, Wood B, Porcher C, Vyas P: Lineage-specific combinatorial action of enhancers regulates mouse erythroid Gata1 expression. Blood. 2009, 115 (17): 3463-3471.CrossRef
5.
Weiss MJ, Keller G, Orkin SH: Novel insights into erythroid development revealed through in vitro differentiation of GATA-1 embryonic stem cells. Genes Dev. 1994, 8 (10): 1184-1197. 10.1101/gad.8.10.1184.CrossRefPubMed
6.
Huang Z, Dore LC, Li Z, Orkin SH, Feng G, Lin S, Crispino JD: GATA-2 reinforces megakaryocyte development in the absence of GATA-1. Mol Cell Biol. 2009, 29 (18): 5168-5180. 10.1128/MCB.00482-09.PubMedCentralCrossRefPubMed
7.
Solar GP, Kerr WG, Zeigler FC, Hess D, Donahue C, de Sauvage FJ, Eaton DL: Role of c-mpl in early hematopoiesis. Blood. 1998, 92 (1): 4-10.PubMed
8.
Fleury M, Petit-Cocault L, Clay D, Souyri M: Mpl receptor defect leads to earlier appearance of hematopoietic cells/hematopoietic stem cells in the Aorta-Gonad-Mesonephros region, with increased apoptosis. Int J Dev Biol. 2010, 54 (6–7): 1067-1074.CrossRefPubMed
9.
Satoh Y, Matsumura I, Tanaka H, Ezoe S, Fukushima K, Tokunaga M, Yasumi M, Shibayama H, Mizuki M, Era T: AML1/RUNX1 works as a negative regulator of c-Mpl in hematopoietic stem cells. J Biol Chem. 2008, 283 (44): 30045-30056. 10.1074/jbc.M804768200.PubMedCentralCrossRefPubMed
10.
Kelly LM, Gilliland DG: Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet. 2002, 3: 179-198. 10.1146/annurev.genom.3.032802.115046.CrossRefPubMed
11.
Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, Steffen B, Matsumura I, Kanakura Y, Bohmer FD: Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood. 2003, 101 (8): 3164-3173. 10.1182/blood-2002-06-1677.CrossRefPubMed
12.
Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, Behre G, Hiddemann W, Tenen DG: Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet. 2001, 27 (3): 263-270. 10.1038/85820.CrossRefPubMed
13.
Pabst T, Mueller BU: Complexity of CEBPA dysregulation in human acute myeloid leukemia. Clin Cancer Res. 2009, 15 (17): 5303-5307. 10.1158/1078-0432.CCR-08-2941.CrossRefPubMed
14.
Szankasi P, Ho AK, Bahler DW, Efimova O, Kelley TW: Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features. Leuk Res. 2011, 35 (2): 200-207. 10.1016/j.leukres.2010.09.018.CrossRefPubMed
15.
Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, Habdank M, Spath D, Morgan M, Benner A: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008, 358 (18): 1909-1918. 10.1056/NEJMoa074306.CrossRefPubMed
16.
Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland MC, Berdel WE, Buchner T: Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol. 2010, 28 (4): 570-577. 10.1200/JCO.2008.21.6010.CrossRefPubMed
17.
Ayala RM, Martinez-Lopez J, Albizua E, Diez A, Gilsanz F: Clinical significance of Gata-1, Gata-2, EKLF, and c-MPL expression in acute myeloid leukemia. Am J Hematol. 2009, 84 (2): 79-86. 10.1002/ajh.21332.CrossRefPubMed
18.
Marcucci G, Maharry K, Radmacher MD, Mrozek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol. 2008, 26 (31): 5078-5087. 10.1200/JCO.2008.17.5554.PubMedCentralCrossRefPubMed
19.
Bennett JM CD, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Propolsals for the classification of acute leukaemias. French-American-British (FAB) Cooperative Group. Br J Haematol. 1976, 33 (4): 451-458. 10.1111/j.1365-2141.1976.tb03563.x.CrossRefPubMed
20.
Harris NL JE, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD: The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol. 1999, 10 (12): 1419-1432. 10.1023/A:1008375931236.CrossRefPubMed
21.
Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK, Goldstone AH: The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001, 98 (5): 1312-1320. 10.1182/blood.V98.5.1312.CrossRefPubMed
22.
McCormick SR, McCormick MJ, Grutkoski PS, Ducker GS, Banerji N, Higgins RR, Mendiola JR, Reinartz JJ: FLT3 mutations at diagnosis and relapse in acute myeloid leukemia: cytogenetic and pathologic correlations, including cuplike blast morphology. Arch Pathol Lab Med. 2010, 134 (8): 1143-1151.PubMed
23.
Chung KY, Morrone G, Schuringa JJ, Wong B, Dorn DC, Malcolm MAS: Enforced expression of an Flt3 internal tandem duplication in human CD34+ cells confers properties of self-renewal and enhanced erythropoiesis. Blood. 2005, 105 (1): 77-84. 10.1182/blood-2003-12-4445.CrossRefPubMed
24.
Falini B, Nicoletti I, Martelli MF, Mecucci C: Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc + AML): biologic and clinical features. Blood. 2007, 109 (3): 874-885.CrossRefPubMed
25.
Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005, 352 (3): 254-266. 10.1056/NEJMoa041974.CrossRefPubMed
26.
Qui Luo XM, Sharon M, Wahl J: Activation and repression of interleukin −12 transcription by Erythroid Krupple-like factor in macrophages. BiolChem. 2004, 279: 18451-18456. 2004
27.
Wu H, Chen Y, Liang J, Shi B, Wu G, Zhang Y, Wang D, Li R, Yi X, Zhang H: Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature. 2005, 438 (7070): 981-987. 10.1038/nature04225.CrossRefPubMed
28.
Balgobind BV, Van den Heuvel-Eibrink MM, De Menezes RX, Reinhardt D, Hollink IH, Arentsen-Peters ST, van Wering ER, Kaspers GJ, Cloos J, de Bont ES: Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica. 2010, 96 (2): 221-230.PubMedCentralCrossRefPubMed
29.
Qian Z, Fernald AA, Godley LA, Larson RA, Le Beau MM: Expression profiling of CD34+ hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci U S A. 2002, 99 (23): 14925-14930. 10.1073/pnas.222491799.PubMedCentralCrossRefPubMed
30.
Bonadies N, Foster SD, Chan W, Kvinlaug BT, Spensberger D, Dawson MA, Spooncer E, Whetton AD, Bannister AJ, Huntly BJ: Genome-Wide Analysis of Transcriptional Reprogramming in Mouse Models of Acute Myeloid Leukaemia. PLoS One. 2011, vol6 (issue1): e16330-JannuaryCrossRef
31.
Hoene VFM, Ivanova A, Wallach T, Berthold F, Dame C: GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes. Br J Cancer. 2009, Oct 20;101 (8): 1481-9. Epub 2009 Aug 25CrossRef
32.
Guido Marcucci KM, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu C-G, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD: Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study. J Clin Oncol. 2008, 26 (31): 5078-5087. 10.1200/JCO.2008.17.5554.PubMedCentralCrossRefPubMed
33.
Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998, 92 (7): 2322-2333.PubMed
34.
Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA: Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004, 103 (4): 1237-1243.CrossRefPubMed
35.
Shaffer LG, Slovak M, Campbell L, ISCN: ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009): Recommendations of the International Standing Committee on Human Cytogenetic Nomenc. 2009, S. Karger AG, Basel (Switzerland), P.O. Box, 4009 2009
36.
Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M, Neubauer A: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002, 99 (12): 4326-4335. 10.1182/blood.V99.12.4326.CrossRefPubMed
37.
Benthaus T, Schneider F, Mellert G, Zellmeier E, Schneider S, Kakadia PM, Hiddemann W, Bohlander SK, Feuring-Buske M, Braess J: Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia. Br J Haematol. 2008, 143 (2): 230-239. 10.1111/j.1365-2141.2008.07328.x.CrossRefPubMed
38.
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD: The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol. 1999, 10 (12): 1419-1432. 10.1023/A:1008375931236.CrossRefPubMed
39.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976, 33 (4): 451-458. 10.1111/j.1365-2141.1976.tb03563.x.CrossRefPubMed
Metadata
Title
Acute myeloid leukemia and transcription factors: role of erythroid Krüppel-like factor (EKLF)
Authors
Rosa Ayala
Joaquin Martínez-López
Florinda Gilsanz
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2012
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-12-25

Other articles of this Issue 1/2012

Cancer Cell International 1/2012 Go to the issue

Primary research

Reduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization

Primary research

Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid

Primary research

The characteristics of bone marrow-derived endothelial progenitor cells and their effect on glioma

Primary research

Caveolin-1 expression is elevated in claudin-low mammary tumor cells

Primary research

Establishment and characterization of two human breast carcinoma cell lines by spontaneous immortalization: Discordance between Estrogen, Progesterone and HER2/neu receptors of breast carcinoma tissues with derived cell lines

Primary research

Enhanced vesicular stomatitis virus (VSVΔ51) targeting of head and neck cancer in combination with radiation therapy or ZD6126 vascular disrupting agent
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits